Insulin Initiation in Insulin-Naive Korean Type 2 Diabetic Patients Inadequately Controlled on Oral Antidiabetic Drugs in Real-World Practice: The Modality of Insulin Treatment Evaluation Study.
10.4093/dmj.2015.39.6.481
- Author:
Sang Soo KIM
1
;
In Joo KIM
;
Yong Ki KIM
;
Kun Ho YOON
;
Ho Young SON
;
Sung Woo PARK
;
Yeon Ah SUNG
;
Hong Sun BAEK
Author Information
1. Department of Internal Medicine, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Korea. injkim@pusan.ac.kr
- Publication Type:Multicenter Study ; Original Article
- Keywords:
Basal insulin;
Diabetes mellitus, type 2;
Korea;
Pragmatic clinical trials as topic
- MeSH:
Body Weight;
Diabetes Mellitus, Type 2;
Humans;
Hypoglycemic Agents*;
Insulin*;
Korea;
Observational Study;
Pragmatic Clinical Trials as Topic;
Prospective Studies
- From:Diabetes & Metabolism Journal
2015;39(6):481-488
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: The Modality of Insulin Treatment Evaluation (MOTIV) study was performed to provide real-world data concerning insulin initiation in Korean type 2 diabetes mellitus (T2DM) patients with inadequate glycemic control with oral hypoglycemic agents (OHAs). METHODS: This multicenter, non-interventional, prospective, observational study enrolled T2DM patients with inadequate glycemic control (glycosylated hemoglobin [HbA1c] > or =7.0%) who had been on OHAs for > or =3 months and were already decided to introduce basal insulin by their physician prior to the start of the study. All treatment decisions were at the physician's discretion to reflect real-world practice. RESULTS: A total of 9,196 patients were enrolled, and 8,636 patients were included in the analysis (mean duration of diabetes, 8.9 years; mean HbA1c, 9.2%). Basal insulin plus one OHA was the most frequently (51.0%) used regimen. After 6 months of basal insulin treatment, HbA1c decreased to 7.4% and 44.5% of patients reached HbA1c <7%. Body weight increased from 65.2 kg to 65.5 kg, which was not significant. Meanwhile, there was significant increase in the mean daily insulin dose from 16.9 IU at baseline to 24.5 IU at month 6 (P<0.001). Overall, 17.6% of patients experienced at least one hypoglycemic event. CONCLUSION: In a real-world setting, the initiation of basal insulin is an effective and well-tolerated treatment option in Korean patients with T2DM who are failing to meet targets with OHA therapy.
